Rochester-based Vaccinex Inc. is a clinical-stage biotech company that creates targeted biologics to combat serious diseases with unmet medical needs. Its chief product is pepinemab, a humanized monoclonal antibody that has finished and will undergo clinical tests on non-small cell lung cancer (NSCLC), Huntington’s Disease, and Alzheimer’s Disease. The company is also developing a preclinical substance named VX5 that is a human antibody to CXCL13 - aimed at fighting multiple sclerosis and other autoimmune disorders.